IMPINJ INC SEC Filings

Chris Diorio, Ph.D., Chief Executive Officer and Director of Impinj Inc. (PI), reported insider transactions dated 09/18/2025. The filing shows non-derivative purchases of 47,039 and 7,036 shares of Common Stock on 09/18/2025 at reported prices of $33.77 and $22.40, respectively. Following those transactions the report lists 351,088 shares beneficially owned directly and 199,362 shares beneficially owned indirectly through DFT L.L.C. The filing also reports derivative entries showing stock options tied to the same amounts and exercise prices, with vesting dates noted as July 3, 2021 and June 11, 2022. The document was signed 09/19/2025.

Chris Diorio, Director and Chief Executive Officer of Impinj Inc. (PI), reported sales of common stock effected under a Rule 10b5-1 trading plan on September 15-16, 2025. The filing lists ten sell transactions that aggregate to 9,096 shares sold at weighted-average prices for each batch ranging from about $179.26 up to $191.76 as detailed in the form. Following these transactions, the filing shows Mr. Diorio directly beneficially owns 297,013 shares and indirectly owns 199,362 shares through DFT L.L.C.

The form includes explanatory notes that the reported amounts and prices reflect aggregated multiple transactions within specified per-share price ranges and that full per-transaction detail is available on request.

Chris Diorio, Chief Executive Officer and Director of Impinj, Inc. (PI), reported a gift disposition of 30,000 common shares on 09/12/2025 under Code G(1). The filing states this transfer is permitted by a lock-up agreement tied to the companys September 2025 0% Convertible Senior Notes offering, allowing Diorio to gift up to 30,000 shares during the lock-up period. After the reported transaction, Diorio beneficially owns 306,109 shares directly and 199,362 shares indirectly via DFT L.L.C. The Form 4 was signed by an attorney in fact on 09/16/2025.

Sylebra Capital and affiliated entities reported owning 1,829,260 shares of Impinj Inc. common stock, equal to 6.29% of the class. This filing is an amendment to a prior Schedule 13D and reflects a disposal of securities executed in the ordinary course of portfolio management. The filing names four reporting persons — Sylebra Capital LLC, Sylebra Capital Ltd, Sylebra Capital Management, Ltd and Daniel Patrick Gibson — and states that they share voting and dispositive power over the reported shares through affiliated investment entities. The amendment attaches a Joint Filing Agreement and otherwise leaves prior Schedule 13D disclosures unchanged.

Impinj, Inc. Form 144 notice shows a proposed sale of 300,000 shares of common stock through Morgan Stanley & Co. LLC on NASDAQ, with an aggregate market value of $58,873,670. The filing reports 1,829,260 shares outstanding, so the proposed sale represents approximately 16.4% of outstanding shares. The securities were acquired on 03/01/2018 via open market purchases and payment was made DVP–Cash. No sales by the reporting person were reported in the past three months. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Chris Diorio, Ph.D., CEO and director of Impinj, Inc. (PI), reported the sale of 10,000 shares of Impinj common stock under a Rule 10b5-1 trading plan effective May 28, 2025. The Form 4 shows multiple off‑market sales on September 8–9, 2025 with weighted‑average prices reported across several price bands from about $190.19 to $198.05. After the reported dispositions, Dr. Diorio is shown as beneficially owning 336,109 shares directly and 199,362 shares indirectly through DFT L.L.C., according to the filing.

Impinj, Inc. completed a private offering of $190 million aggregate principal amount of 0% Convertible Senior Notes due 2029 and entered into an indenture with U.S. Bank Trust Company as trustee. The notes are senior unsecured, mature on September 15, 2029, and are convertible based on an initial rate of 3.7398 shares per $1,000, equivalent to a conversion price of about $267.39 per share, a 37.50% premium to the $194.47 share price on September 3, 2025.

Net proceeds of approximately $183.6 million, together with cash on hand, were used to exchange $190.0 million principal of 1.125% Convertible Senior Notes due 2027 for about $190.5 million in cash and approximately 0.8 million shares of common stock, leaving $97.5 million of the 2027 notes outstanding. Impinj also entered into capped call transactions with several banks, economically matching the notes’ conversion profile with a strike around $267.39 and an initial cap price of about $340.32 per share, designed to reduce potential dilution or offset certain cash payments upon conversion up to that cap.

Chris Diorio, Ph.D., Chief Executive Officer and Director of Impinj, Inc. (PI), reported sales of 10,000 shares of common stock under a Rule 10b5-1 trading plan. The transactions occurred on September 2–3, 2025 and were effected under a trading plan effective May 28, 2025. The sales were reported as multiple transactions with weighted-average prices reported in ranges from $180.00 to $190.405 per share across the trades. Following the reported transactions, Dr. Diorio is shown as beneficially owning 346,109 shares directly and 199,362 shares indirectly (via DFT L.L.C.), for a combined total of 545,471 shares. The Form 4 was signed by an attorney-in-fact on behalf of Dr. Diorio on September 3, 2025.

Impinj, Inc. reported that it has issued a press release announcing its intention to offer $175 million aggregate principal amount of Convertible Senior Notes due 2029. The notes are expected to be sold in a private placement to qualified institutional buyers under Rule 144A of the Securities Act. The announcement is provided through a press release attached as Exhibit 99.1, giving more detail on this planned financing transaction.